Profile data is unavailable for this security.
About the company
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
- Revenue in USD (TTM)8.12m
- Net income in USD-93.14m
- Incorporated2018
- Employees387.00
- LocationMeiraGTx Holdings PLC450 E 29th St Fl 15NEW YORK 10016-8367United StatesUSA
- Websitehttps://meiragtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sutro Biopharma Inc | 169.36m | -124.45m | 295.89m | 304.00 | -- | 1.94 | -- | 1.75 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
PepGen Inc | 0.00 | -89.14m | 303.08m | 64.00 | -- | 1.94 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Lyell Immunopharma Inc | 54.00k | -210.26m | 312.32m | 224.00 | -- | 0.5512 | -- | 5,783.77 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Korro Bio Inc | 0.00 | -92.22m | 312.35m | 92.00 | -- | 1.57 | -- | -- | -30.51 | -30.51 | 0.00 | 21.34 | 0.00 | -- | -- | 0.00 | -56.06 | -31.55 | -59.82 | -36.48 | -- | -- | -- | -365.87 | -- | -167.13 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
Monte Rosa Therapeutics Inc | 5.76m | -130.41m | 312.39m | 103.00 | -- | 1.39 | -- | 54.24 | -2.24 | -2.24 | 0.0967 | 3.66 | 0.0185 | -- | 1.05 | 43,300.75 | -41.88 | -- | -46.47 | -- | -- | -- | -2,264.53 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Instil Bio Inc | 0.00 | -119.58m | 315.31m | 49.00 | -- | 1.62 | -- | -- | -18.39 | -18.39 | 0.00 | 29.98 | 0.00 | -- | -- | 0.00 | -34.04 | -- | -35.48 | -- | -- | -- | -- | -- | -- | -- | 0.2958 | -- | -- | -- | 30.06 | -- | -- | -- |
Aldeyra Therapeutics Inc | 0.00 | -37.87m | 317.31m | 10.00 | -- | 3.23 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
ADC Therapeutics SA | 66.75m | -214.86m | 318.10m | 273.00 | -- | -- | -- | 4.77 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
MeiraGTx Holdings PLC | 8.12m | -93.14m | 320.31m | 387.00 | -- | 3.35 | -- | 39.44 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
Heron Therapeutics Inc | 136.36m | -48.13m | 321.54m | 126.00 | -- | -- | -- | 2.36 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
XOMA Royalty Corp | 15.24m | -25.10m | 323.51m | 13.00 | -- | 3.22 | -- | 21.23 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
Inozyme Pharma Inc | 0.00 | -88.56m | 324.34m | 59.00 | -- | 3.40 | -- | -- | -1.46 | -1.46 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -57.76 | -45.00 | -63.48 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3244 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
AC Immune SA | 18.05m | -70.52m | 334.42m | 133.00 | -- | 2.33 | -- | 18.53 | -0.748 | -0.748 | 0.1949 | 1.45 | 0.0787 | -- | 28.76 | 135,723.90 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
GH Research PLC | -100.00bn | -100.00bn | 337.66m | 49.00 | -- | 1.70 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -69.64m | 339.86m | 164.00 | -- | 1.44 | -- | -- | -0.557 | -0.557 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -23.08 | -- | -23.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Perceptive Advisors LLCas of 31 Mar 2024 | 11.33m | 17.62% |
Adage Capital Management LPas of 31 Mar 2024 | 5.29m | 8.23% |
Prosight Management LPas of 31 Mar 2024 | 4.02m | 6.25% |
683 Capital Management LLCas of 31 Mar 2024 | 2.50m | 3.89% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.94m | 3.01% |
Royce & Associates LPas of 31 Mar 2024 | 692.12k | 1.08% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 569.82k | 0.89% |
Geode Capital Management LLCas of 30 Jun 2024 | 495.62k | 0.77% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 413.66k | 0.64% |
Laurion Capital Management LPas of 31 Mar 2024 | 367.94k | 0.57% |